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Abstract
Background: Conflicting with clinical practice guidelines, recent studies demonstrated that serum potassium
concentrations (SPC) of ≥4.5 mEq/l were associated with increased mortality in patients with acute myocardial
infarction (AMI). This study examined the association between SPC and long-term mortality following AMI in
patients recruited from a population-based registry.
Methods: Included in the study were 3347 patients with AMI aged 28–74 years consecutively hospitalized between 1
January 2000 and 31 December 2008 and followed up until 31 December 2011. Patients were categorized into five SPC
groups (<3.5, 3.5 to <4.0, 4.0 to <4.5, 4.5 to <5.0, and ≥5.0 mEq/l). The outcome of the study was all-cause mortality.
Cox regression models adjusted for risk factors, co-morbidities and in-hospital treatment were constructed.
Results: In our study population, 249 patients (7.4%) had a low SPC (<3.5 mEq/l) and 134 (4.0%) patients had a high
SPC (≥5.0 mEq/l). Patients with SPC of ≥5.0 mEq/l had the highest long-term mortality (29.9%) and in the adjusted
model, their risk of dying was significantly increased (HR 1.46, 95% CI 1.03 to 2.07) compared to patients with SPC
between 4.0 and <4.5 mEq/l. Analyses of increasing observation periods showed a trend towards a higher risk of dying
in patients with SPC between 4.5 and <5.0 mEq/l.
Conclusion: An admission SPC of ≥5.0 mEq/l might be associated with an increased mortality risk in patients with AMI.
Patients with an admission SPC between 4.5 and <5.0 mEq/l might have an increased mortality risk in the first few
years following AMI.
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Background
Hypo- and hyperkalemia have been shown to increase car-
diovascular and total mortality in patients with acute myo-
cardial infarction (AMI) [1–3]. Hypokalemia refers to a
serum potassium concentration (SPC) of <3.5 mEq/l,
occurs frequently in hospitalized patients [1] and is associ-
ated with ventricular arrhythmias as well as an overall
poor prognosis after cardiovascular events [2, 4]. Hyperka-
lemia is defined as a SPC of >5.0 mEq/l and can have a
variety of adverse consequences, such as cardiac arrhyth-
mias, in patients hospitalized after a cardiovascular event
[3]. In patients with AMI recommended SPC are between
4.0 and 5.0 mEq/l [5, 6] or above 4.5 mEq/l [7].
In contrast to clinical practice guidelines [4–7], recent
studies in patients with AMI concluded that a SPC of
≥4.5 mEq/l was associated with an increased in-hospital
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and 3-year mortality, respectively [8–10]. To examine
whether these findings are valid for a longer observation
period, we analyzed the association between SPC and
long-term mortality in patients recruited from a
population-based myocardial infarction registry.
Methods
Data source and study population
As part of the World Health Organization (WHO) project
MONICA (Monitoring Trends and Determinants in Car-
diovascular disease) the population-based Augsburg Myo-
cardial Infarction Registry was established in 1984 [11].
MONICA was terminated in 1995 and the registry be-
came part of the KORA (Cooperative Health Research in
the Region of Augsburg) framework. Since the registry
commenced, all cases of coronary death and non-fatal
AMI of the 25- to 74-year old study population in the city
of Augsburg and two adjacent counties (about 600,000 in-
habitants) have been continuously registered. Patients ad-
mitted to one of the eight hospitals in the study area were
included. Methods of case identification, diagnostic classi-
fication of events as well as data quality control have been
described in detail elsewhere [11, 12]. Data collection and
follow-up questionnaires have been approved by the ethics
committee of the Bavarian Medical Association (Bayer-
ische Landesärztekammer) and have been performed in
accordance with the Declaration of Helsinki. All study
participants gave written informed consent.
Included in our cohort study were all patients with a
first ever AMI consecutively registered between 1
January 2000 and 31 December 2008, whose survival
time exceeded 28 days after AMI. Patients were followed
up until December 2011. From 4429 patients, we ex-
cluded those with missing SPC (n = 164) as well as those
with incomplete data on any of the covariates included
in our Cox regression models (n = 918). The final study
population comprised 3347 male and female patients
aged 28–74 years with a first ever AMI, who survived
more than 28 days after the event.
Data collection
Interviews with study participants were conducted by
trained study nurses during hospital stay using a stan-
dardized questionnaire [13, 14]. Patient demographics,
risk factors and co-morbidities were covered during the
interviews. Laboratory values, AMI characteristics,
medical and drug treatment as well as in-hospital compli-
cations were obtained from the patients’ medical record.
Patients’ SPC was determined at hospital admission
and expressed in mEq/l. Patients were divided into five
groups according to their SPC: < 3.5, 3.5 to <4.0, 4.0 to
<4.5, 4.5 to <5.0, ≥5.0 mEq/l.
Renal function was assessed by calculating the esti-
mated glomerular filtration rate (eGFR) using the
Modification of Diet in Renal Disease (MDRD) study
equation (eGFR (ml/min/1.73 m2) = 186.3 × (serum cre-
atinine−1.154) x (age−0.203) × 0.742 (if female) × 1.212 (if
black)) [15]. Since creatinine values were only available
from 2005 onwards, missing values were incorporated in
the analyses as part of a dummy-coded variable. An
eGFR of <60 ml/min/1.73m2 indicates renal impairment
and is independently associated with increased all-cause
as well as cardio-vascular mortality [16, 17]. Therefore,
eGFR values were classified into three categories: <60,
≥60 ml/min/1.73m2, and missing values.
Whether patients had been previously diagnosed with
angina pectoris, hypertension, hyperlipidemia, diabetes
and stroke (yes/no) as well as patients’ smoking status
(smoker/ex-smoker/never-smoker) was determined dur-
ing the interviews and, with the exception of stroke and
smoking status, confirmed by chart review. Hemoglobin
and glucose concentration were measured at hospital ad-
mission. The highest value of creatine kinase-myocardial
band (CK-MB) measured during hospital stay was in-
cluded in our analyses to serve as a marker for the ex-
tent of myocardial injury [18]. Whether any in-hospital
revascularization (coronary artery bypass surgery, percu-
taneous coronary intervention (PCI) or thrombolysis)
was performed during hospital stay was included in the
analysis as a single covariate (yes/no). Furthermore,
treatment with the following medications at hospital dis-
charge were documented (yes/no): antiplatelet agents,
beta-blockers, angiotensin-converting enzyme inhibitors
(ACEIs) or angiotensin-receptor blockers (ARBs), statins,
diuretics, calcium channel blockers, nitrates, insulin and
other antidiabetic agents. Administering four evidence-
based medications (EBMs; antiplatelet agents, beta-
blockers, ACEIs/ARBs, statins) after AMI is considered
a standard of care since 2004 and was included as a co-
variate in our analyses (yes/no). A variable was created
summarizing the occurrence of in-hospital complica-
tions, such as cardiac arrest, pulmonary edema, brady-
cardia, re-infarction, ventricular tachycardia, ventricular
fibrillation or cardiogenic shock (yes/no). A reduced left
ventricular ejection fraction (LVEF) was noted if echo-
cardiography, ventriculography or radionuclide ventricu-
lography revealed a LVEF of < 30% (yes/no).
The outcome of this study was all-cause mortality after
more than 28 days following AMI. It was determined by
monitoring the vital status of study participants through
population registries in- and outside the study region
until 31 December 2011.
Statistical analyses
Categorical variables were expressed as percentages,
continuous variables as mean value with standard devi-
ation (SD) and continuous variables that proved not to
be normally distributed as median with interquartile
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range (IQR). Potential covariates were cross-tabulated
with the five SPC groups. Differences in frequencies
were tested using Chi2 or Kruskal-Wallis rank-sum test.
To evaluate age differences among the SPC groups, a
one-way ANOVA (analysis of variance) was performed.
Kaplan-Meier plots were generated along with bivariate
log-rank tests against survival to test for statistical
significance.
To analyze the association between SPC and long-
term mortality, Cox proportional hazards regression
models were constructed. Patients with a SPC of 4.0 to
<4.5 mEq/l served as reference group. An unadjusted
model followed by a minimally adjusted model, addition-
ally including the covariates sex and age, were calcu-
lated. A parsimonious model was created using
backward elimination. Covariates that proved to be sig-
nificantly associated with mortality in the univariate ana-
lysis were entered into the full model. Covariates were
only included into the parsimonious model if they made
a statistically significant contribution (p < 0.05) to the
model. The final model was adjusted for prior angina
pectoris, hypertension, hyperlipidemia, stroke, smoking
status, peak CK-MB, any revascularization treatment
and all four EBMs at discharge as well as the following
discharge medications: diuretics, calcium channel
blockers and insulin. The assumption of proportional
hazards (parallel lines of log (−log(event)) versus log of
event times) was tested graphically. Covariates violating
the proportional hazards assumption were included as
time-dependent covariates into the full model prior to
backwards elimination. The covariates sex and age were
forced to stay in the models. Multicollinearity among
the independent variables was examined by assessing
variance inflation factors (VIF) in the full model prior to
backward selection [19].
Additionally, parsimonious models were calculated for
observation periods of one, three, five and ten years in
order to detect potential changes in HRs. A Cox regres-
sion model was calculated for patients excluded from
the study due to missing data on covariates as a sensitiv-
ity analysis. To ensure comparability with the results of
our study population, we adjusted this model for all co-
variates that were included in our main parsimonious
model. Covariates providing information on stroke prior
to AMI, smoking status and peak CK-MB were respon-
sible for 95.3% (n = 875) of all missing values (n = 918)
and, thus, could not be included in this model. Finally,
since information on eGFR were only available from
2005 onwards, we calculated a separate Cox regression
model using backward elimination and only including
patients who were enrolled from 2005 onwards.
Statistical test results were considered significant if the
p value was <0.05. All statistical analyses were performed
using SAS software, version 9.2 (SAS Institute).
Results
The study sample comprised 3347 patients with a first
ever AMI and a mean age of 59.9 years (SD 9.8). Male
patients accounted for 75.6% (n = 2531) of the sample.
The median follow-up time was 6.1 years (IQR 4.2).
Baseline characteristics
Baseline characteristics according to SPC are shown in
Table 1. On average, patients with AMI had a SPC of
4.1 mEq/l (SD 0.5). The five SPC groups significantly dif-
fered from each other in terms of sex, history of diabetes
and hypertension, smoking status, AMI type, laboratory
values, medications received at hospital discharge (di-
uretics, insulin and other antidiabetic agents) and occur-
rence of any in-hospital complications (see Table 1).
Serum potassium concentration and long-term mortality
Long-term mortality in the whole study population was
14.3% (n = 481). The highest mortality of 29.9% (n = 40)
was observed in patients with SPC of ≥5.0 mEq/l and
the lowest (12.6%, n = 134) in patients with SPC of 3.5
to <4.0 mEq/l. Kaplan-Meyer survival curves along with
the corresponding log-rank test demonstrated statisti-
cally significant differences in survival between the five
serum potassium groups (see Fig. 1).
Results of the Cox regression analyses are shown in
Table 2. In the unadjusted model, patients with SPC of
≥5.0 mEq/l had a significantly increased mortality risk
compared to the reference group (unadjusted HR 2.49,
95% CI 1.77–3.50). Adjusting for sex and age resulted in
a slight decrease of the HRs. Further adjusting for hyper-
tension, hyperlipidemia, stroke, smoking status, peak
CK-MB, any in-hospital revascularization, all four EBMs
at discharge as well as diuretics, calcium channel
blockers and insulin treatment at discharge, patients
with SPC of ≥5.0 mEq/l still were at an increased risk of
dying (adjusted HR 1.46, 95% CI 1.03 to 2.07). Patients
with SPC of 3.5 to <4.5 mEq/l and <3.5 mEq/l showed
the lowest long-term mortality risk compared to the ref-
erence group. However, these results did not prove to be
statistically significant.
In the analysis of patients who were enrolled from 2005
onwards, those with a SPC of 4.5 - <5.0 mEq/l and those
with a SPC ≥5.0 mEq/l did not have significantly increased
HRs. Additionally, patients with a SPC of 3.5 - <4.0 mEq/l
had a significantly decreased mortality risk compared to the
reference group (data not shown). Except for the hyperten-
sion and angina pectoris, the same covariates remained in
the model as in the parsimonious model shown in Table 2.
1-, 3-, 5- and 10-year mortality risks
Table 3 shows the results of the parsimonious regression
models calculated for different observation periods as
well as the corresponding mortality for each SPC group.
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Table 1 Baseline characteristics of patients with acute myocardial infarction by admission serum potassium concentration (n = 3347)












Female, n (%) 99 (39.8) 276 (26.0) 306 (21.8) 103 (20.7) 32 (23.9) <0.0001
Age (years), mean ± SD 60.1 ± 9.6 59.9 ± 9.9 59.6 ± 9.7 60.4 ± 9.8 61.1 ± 9.1 0.3156
Risk factors and co-morbidities, n (%)
Angina pectoris 31 (12.5) 135 (12.7) 196 (13.9) 72 (14.5) 23 (17.2) 0.5858
Hypertension 199 (79.9) 813 (76.7) 1033 (73.5) 383 (76.9) 111 (82.8) 0.0278
Hyperlipidemia 173 (69.5) 737 (69.5) 998 (71.0) 336 (67.5) 99 (73.9) 0.5139
Stroke 12 (4.8) 56 (5.3) 77 (5.5) 29 (5.8) 14 (10.5) 0.1640
Diabetes mellitusa 59 (23.8) 273 (25.8) 376 (26.7) 172 (34.5) 58 (43.3) <0.0001
Smoking status
Current smoker 83 (33.3) 404 (38.1) 552 (39.3) 203 (40.8) 52 (38.8) 0.0140
Ex-smoker 71 (28.5) 318 (30.0) 423 (30.1) 156 (31.3) 55 (41.0)
Never-smoker 95 (38.2) 338 (31.9) 431 (30.7) 139 (27.9) 55 (20.2)
Clinical characteristics, n (%)
AMI typeb
STEMI 125 (50.4) 489 (46.5) 555 (39.8) 187 (28.3) 47 (35.3) 0.0007
NSTEMI 114 (46.0) 516 (49.1) 768 (55.1) 267 (54.7) 79 (59.4)
Bundle branch block 9 (3.6) 46 (4.4) 70 (5.0) 34 (7.0) 7 (5.3)
LVEF <30%c 16 (9.5) 84 (10.9) 104 (10.5) 49 (13.7) 13 (14.6) 0.3453
Laboratory values, median (IQR)
Admission creatinine (mg/dl)d 0.96 (0.8–1.2) 0.97 (0.8–1.1) 0.97 (0.8–1.1) 1.01 (0.8–1.2) 1.14 (1.0–1.5) <0.0001
Admission hemoglobin (g/l)d 141 (131–151) 145 (136–155) 146 (137–156) 145 (135–154) 145 (129–158) 0.0079
Admission troponin-I (ng/ml)e 0.32 (0.1–2.7) 0.41 (0.1–3.2) 0.66 (0.1–3.8) 0.73 (0.2–5.9) 1.21 (0.2–4.9) <0.0001
Peak CK-MB (U/l) 51 (15–122) 48 (18–119) 41 (16–105) 38 (15–99) 41 (15–84) 0.0462
Admission glucose (mg/dl) 143 (119–168) 130 (112–162) 126 (108–161) 131 (112–179) 152 (121–224) <0.0001
eGFR (ml/min/1.73m2)d 76.2 (61.2–96.8) 78.9 (66.2–94.0) 80.4 (67.3–95.1) 77.3 (61.1–91.7) 65.8 (47.2–80.3) <0.0001
eGFR <60 (ml/min/1.73m2), n (%)d 29 (23.6) 69 (14.2) 96 (15.3) 56 (23.5) 24 (40.0) <0.0001
In-hospital treatment, n (%)
Coronary angiography 237 (95.2) 1002 (94.5) 1331 (94.7) 458 (92.0) 120 (89.6) 0.0306
PCIf 170 (68.3) 757 (71.4) 970 (69.0) 339 (68.1) 84 (62.7) 0.2392
CABG 37 (14.9) 153 (14.4) 247 (17.6) 87 (17.5) 22 (16.4) 0.2638
Thrombolysisg 38 (18.9) 137 (18.0) 130 (14.0) 46 (13.7) 8 (9.2) 0.0338
Any revascularization treatment 212 (85.1) 934 (88.1) 1225 (87.1) 427 (85.7) 108 (80.6) 0.1199
Medication at hospital discharge
Antiplatelet agents 236 (94.8) 1028 (97.0) 1357 (96.5) 484 (97.2) 128 (95.5) 0.4053
Beta-blockers 236 (94.8) 1023 (96.5) 1350 (96.0) 474 (95.2) 124 (92.5) 0.1863
ACEIs/ARBs 217 (87.2) 883 (83.3) 1151 (81.9) 425 (85.3) 108 (80.6) 0.1436
Statins 219 (88.0) 949 (89.5) 1263 (89.8) 443 (89.0) 115 (85.8) 0.6086
All four EBMs 176 (70.7) 763 (72.0) 1004 (71.4) 364 (73.1) 85 (63.4) 0.2770
Diuretics 147 (59.0) 533 (50.3) 643 (45.7) 247 (49.6) 86 (64.2) <0.0001
Calcium channel blockers 41 (16.5) 120 (11.3) 174 (12.4) 51 (10.2) 22 (16.4) 0.0598
Nitrates 3 (1.2) 38 (3.6) 61 (4.3) 22 (4.4) 8 (6.0) 0.1066
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The highest mortality was found in patients with a SPC
of ≥5.0 mEq/l across all observation periods, whereas
the lowest mortality was mainly found in patients with a
SPC between 3.5 and <4.0 mEq/l. After a one-year ob-
servation period, the mortality risk of patients with a
SPC between 4.5 and <5.0 mEq/l was increased by 96%
(adjusted HR 1.96, 95% CI 1.10 to 3.48). Although the
results for three- and five-year observation periods did
not meet statistical significance, a trend towards an in-
creased mortality risk in patients with SPC between 4.5
and <5.0 mEq/l could be identified (Table 3). After a
ten-year observation period, only the HRs of patients
with a SPC of ≥5.0 mEq/l were significantly increased.
Mortality in patients excluded from the study
In patients excluded from the study due to partly miss-
ing data on relevant covariates, an increased long-term
mortality risk was found in patients with SPC between
4.5 and <5.0 mEq/l (adjusted HR 1.43, 95% CI 1.00 to
2.04) and ≥5.0 mEq/l (adjusted HR 2.40, 95% CI 1.55 to
3.67) compared to the reference group (see Table 4).
Discussion
In the present study, we analyzed the association be-
tween admission SPC and long-term all-cause mortality
in patients with AMI. Mortality risks were significantly
increased in the highest SPC group (≥5.0 mEq/l).
Table 1 Baseline characteristics of patients with acute myocardial infarction by admission serum potassium concentration (n = 3347)
(Continued)
Insulin 19 (7.6) 66 (6.2) 128 (9.1) 56 (11.2) 27 (20.2) <0.0001
Other antidiabetic agents 11 (4.4) 103 (9.7) 149 (10.6) 84 (16.9) 23 (17.2) <0.0001
Any In-hospital complicationsh, i,
n (%)
53 (21.5) 162 (15.4) 201 (14.4) 89 (17.9) 24 (18.3) 0.0340
SPC, Serum potassium concentration; SD, Standard deviation; AMI, Acute myocardial infarction; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-
elevation myocardial infarction; LVEF,
Left-ventricular ejection fraction; IQR, Interquartile range, CK-MB, Creatine kinase-myocardial band; eGFR, Estimated glomerular filtration rate; PCI, Percutaneous
coronary intervention; CABG, Coronary artery bypass graft; ACEIs, Angiotensin-converting enzyme inhibitors; ARBs, Angiotensin-receptor blockers; EBMs,








h Including cardiac arrest, pulmonary edema, bradycardia, re-infarction, ventricular tachycardia, ventricular fibrillation and cardiogenic shock occurring during
hospital stay
in = 3317
Fig. 1 Kaplan-Meier curves of 12-year survival for the five admission serum potassium concentration groups
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Analyses covering different observation periods showed
a trend towards increased mortality risks in patients with
SPC between 4.5 and <5.0 mEq/l as well as a significant
association between a SPC of ≥5.0 mEq/l and increased
mortality after a ten-year observation period.
In contrast to recent observational studies [8–10], our
results for the total observation period do not suggest
changing current clinical practice guidelines regarding
desirable SPC in patients with AMI. A significantly in-
creased long-term mortality risk was found only in pa-
tients with SPC of ≥5.0 mEq/l. However, our findings for
shorter observation periods are partly comparable to the
ones reported in recent studies. A study in 38,689 pa-
tients with AMI recruited from the Cerner Health Facts
database and a Korean study in 1924 patients with AMI
reported U-shaped associations between mean SPC and
in-hospital and three-year mortality and found signifi-
cantly increased risks in both patients with mean SPC of
<3.5 mEq/l and ≥4.5 mEq/l [8, 9]. In addition to mean
SPC, Goyal et al. analyzed the association between SPC
Table 2 Cox regression models for long-term mortality following acute myocardial infarction by admission serum potassium
concentration (n = 3347)
Admission SPC,
mEq/l
Unadjusted Model Minimal Modela Parsimonious Modelb
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
<3.5 0.98 (0.67–1.42) 0.9125 0.97 (0.68–1.44) 0.9420 0.92 (0.63–1.34) 0.6686
3.5 - <4.0 0.93 (0.74–1.15) 0.4871 0.88 (0.71–1.10) 0.2593 0.87 (0.70–1.09) 0.2297
4.0 - <4.5 1 (Ref.) 1 (Ref.) 1 (Ref.)
4.5 - <5.0 1.18 (0.91–1.53) 0.2176 1.15 (0.88–1.49) 0.3038 1.08 (0.83–1.41) 0.5582
≥5.0 2.49 (1.77–3.50) <0.0001 2.31 (1.64–3.25) <0.0001 1.46 (1.03–2.07) 0.0360
SPC, Serum potassium concentration; HR, Hazard Ratio; CI, Confidence Interval
aAdjusted for sex and age
bAdjusted for sex, age, angina pectoris, hypertension, hyperlipidemia, stroke, smoking status, peak creatine kinase - mycoardial band (CK-MB), any
revascularization treatment (coronary artery bypass surgery, percutaneous coronary intervention (PCI) or thrombolysis), all four evidence-based medications (EBMs)
at discharge (antiplatelet agents, beta-blockers, ACEIs/ARBs (Angiotensin-converting enzyme inhibitors/Angiotensin receptor blockers), statins), diuretics at dis-
charge, calcium channel blockers at discharge, insulin at discharge
Table 3 Adjusted Cox regression models for observation




HR (95% CI) p Value
1-year observation
period (>28 days to
one year)
< 3.5 1.04 (0.43–2.55) 0.9269
3.5 - <4–0 0.92 (0.51–1.67) 0.7924
4.0 - <4.5 1 (Ref.)
4.5 - <5.0 1.96 (1.10–3.48) 0.0230
≥5.0 1.22 (0.49–3.04) 0.6638
3-year observation
period (>28 days to
3 years)
<3.5 0.60 (0.31–1.16) 0.1268
3.5 - <4–0 0.72 (0.50–1.04) 0.0780
4.0 - <4.5 1 (Ref.)
4.5 - <5.0 1.39 (0.96–2.00) 0.0799
≥5.0 1.29 (0.75–2.21) 0.3560
5-year observation
period (>28 days to
5 years)
<3.5 0.79 (0.49–1.29) 0.3423
3.5 - <4–0 0.78 (0.58–1.04) 0.0901
4.0 - <4.5 1 (Ref.)
4.5 - <5.0 1.32 (0.97–1.80) 0.0811
≥5.0 1.40 (0.91–2.14) 0.1232
10-year observation
period (>28 days to
10 years)
<3.5 0.92 (0.63–1.34) 0.6527
3.5 - <4–0 0.85 (0.68–1.06) 0.1463
4.0 - <4.5 1 (Ref.)
4.5 - <5.0 1.08 (0.83–1.41) 0.5650
≥5.0 1.44 (1.02–2.05) 0.0218
SPC, Serum potassium concentration; HR, Hazard ratio; CI, Confidence interval
aAdjusted for sex, age, angina pectoris, hypertension, hyperlipidemia, stroke,
smoking status, peak creatine kinase -myocardial band (CK-MB), any
revascularization treatment (coronary artery bypass surgery, percutaneous
coronary intervention (PCI) or thrombolysis), all four medications at discharge
(antiplatelet agents, beta-blockers, ACEIs/ARBs (Angiotensin-converting enzyme
inhibitors/Angiotensin receptor blockers), statins), diuretics at discharge, calcium
channel blockers at discharge, insulin at discharge
Table 4 Adjusted Cox regression model for patients excluded




HR (95% CI) p Value
<3.5 1.37 (0.80–2.33) 0.2481
3.5 - <4–0 1.03 (0.73–1.44) 0.8840
4.0 - <4.5 1 (Ref.)
4.5 - <5.0 1.43 (1.00–2.04) 0.0486
≥5.0 2.40 (1.55–3.67) <0.0001
SPC, Serum potassium concentration; HR, Hazard ratio; CI, Confidence interval
aAdjusted for age, sex, angina pectoris, hypertension, hyperlipidemia, any
revascularization therapy (coronary artery bypass surgery, percutaneous coronary
intervention (PCI) or thrombolysis), all four evidence-based medications (EBMs) at
discharge (antiplatelet agents, beta-blockers, ACEIs/ARBs (Angiotensin-converting
enzyme inhibitors/Angiotensin receptor blockers), statins), diuretics at discharge,
calcium channel blockers at discharge, insulin at discharge
b Not adjusted for stroke, smoking status and peak creatine kinase -
myocardial band (CK-MB)
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measured at hospital admission and in-hospital mortality
[8]. The HRs were attenuated yet still significantly in-
creased in patients with SPC ≥4.5 mEq/l. In line with
those findings, patients with SPC between 4.5 and
<5.0 mEq/l had an increased mortality risk in our study
population after a one-year observation period. A similar
trend, yet not statistically significant, was found for
three- and five-year observation periods. Our analysis of
patients excluded from the study also suggests that an
increased risk of dying might already be present in pa-
tients with SPC between 4.5 and <5.0 mEq/l. In patients
with AMI, SPC between 4.5 and <5.0 mEq/l might
therefore negatively affect survival during the first few
years following the event, whereas in the long run, SPC
of ≥5.0 mEq/l might be more harmful. A similar trend
was demonstrated in another study in AMI patients
[10]. In this study, the odds ratios of patients with SPC
between 4.5 and ≤5.0 mEq/l were significantly increased
after one and five years of follow-up. However, the OR
deviated only marginally from the reference group after
a ten-year follow-up [10].
Studies conducted in prior years examined in-hospital
outcomes associated with SPC, but had low statistical
power to detect higher mortality risks due to small study
populations. These studies concluded that patients with
AMI and hypokalemia had an increased risk for cardiac
arrhythmias [20, 21] and a higher in-hospital mortality
[22]. One study found no significant difference in in-
hospital mortality in patients with AMI and hypo- or
normokalemia [23]. Comparability with these studies is
limited not only because they focused on in-hospital
outcomes, but also due to methodological differences
and the fact that AMI treatment has changed
substantially both in terms of revascularization and drug
treatment.
In contrast to earlier studies [7–9, 22, 24], we did not
detect increased mortality risks in patients with low
SPC. These results might be explained by an improved
treatment of patients with AMI counteracting hypokal-
emia. Apart from beneficial effects on survival,
medications routinely administered after AMI, such as
beta-blockers, prevent hypokalemia [8, 23]. Furthermore,
hypokalemia affects morbidity and mortality in patients
with an established cardiovascular event [7, 22, 25, 26].
Especially patients with AMI had an increased risk for
ventricular arrhythmias even if their SPC was only
mildly decreased [1, 3, 7]. Additionally, changes in SPC
subsequent to hospital admission occur frequently. A re-
cent study in patients with heart failure concluded that
the SPC measured within 48 h after hospital admission
is often abnormal and increases during hospitalization
[27]. SPC in our study was only measured at hospital ad-
mission and we did not know if and how hypo-or hyper-
kalemia were treated during hospital stay. Improved
medical treatment of AMI and of hypokalemia in AMI
patients might have positively influenced long-term sur-
vival in our study population with low SPC at hospital
admission.
Potassium homeostasis primarily depends on a normal
renal function [7] and both hypo- and hyperkalemia can
occur due to impaired renal excretion [1, 2]. According
to a large-scale study in 118,753 patients with AMI,
renal impairment is an important long-term predictor of
mortality [28]. Furthermore, hyperkalemia has been
demonstrated to be one of the largest risk factors for all-
cause mortality in patients with an established cardiovas-
cular disease and impaired renal function [29]. In our
study population, patients with high SPC had a lower
eGFR than the reference group, indicating renal impair-
ment. However, the corresponding covariate did not
make it into the final parsimonious model. Nevertheless,
we cannot rule out the possibility of bias since the ad-
mission creatinine level, and consequently the eGFR,
was only available from 2005 onwards in our data set. In
the analysis including only patients enrolled from 2005
onwards, we did not find significantly increased mortal-
ity risks in those with a SPC of 4.5- <5.0 mEq/l and
≥5.0 mEq/l, respectively.
In the present study we focused on long-term mortal-
ity and, therefore, patients who died within 28 days after
AMI were excluded. The excluded patients had a SPC of
4.4 mEq/l (SD 0.8), while the actual study population
had a mean SPC of 4.1 mEq/l (SD 0.5) (data not shown).
Patients who died within 28 days were more likely to
have extreme SPC (<3.5 mEq/l and ≥5.0 mEq/l), they
were overall sicker and older than the included patients
(data not shown). Therefore, including them into the
analysis would have further increased the mortality risk
estimates for patients with high SPC.
This study is characterized by several strengths. To
our knowledge this is the first longitudinal study with an
observation period of more than three years. Data were
collected in the framework of a population-based regis-
try with consecutive enrollment. Important covariates
such as in-hospital treatment and complications,
medication received at hospital discharge as well as risk
factors and co-morbidities were included.
The following limitations should be considered. We
did not have the possibility to distinguish between
potassium-sparing versus non-potassium-sparing di-
uretics. In addition, our results do not apply to patients
with AMI who are older than 74 years. Data on ethnicity
was not collected in the framework of the registry and,
therefore, the results might not be generalizable to all
ethnic groups. Patients with AMI were enrolled between
2000 and 2008 for this study and treatment strategies
most likely improved during this time span both for
hypo- or hyperkalemia after AMI as well as AMI itself.
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Data on the treatment of AMI was included in the ana-
lysis; however, data on the treatment of abnormal SPC
was not collected in the framework of the registry.
Finally, due to the observational design of our study we
might not have considered all relevant confounders and
we cannot exclude the possibility of reverse causation.
Conclusion
Based on our analysis, an admission SPC of ≥5.0 mEq/l
might be associated with an increased mortality risk in
patients with AMI. Furthermore, our results indicate
that also patients with admission SPC between 4.5 and
<5.0 mEq/l may experience a higher mortality risk in the
first few years following AMI. Due to the limited data
on renal function in our study, further long-term studies
are needed to provide evidence on the relevance of
admission SPC in patients with AMI.
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